Top Medical News
2 days ago
New drug applications approved by US FDA as of 1 - 15 August 2017 which includes New Molecular Entities (NMEs) and new biologics. It does not include Tentative Approvals. Supplemental approvals may have occurred since the original approval date.
5 days ago
A high burden of metabolic risk factors may increase the risk of hepatocellular carcinoma (HCC) in men with chronic hepatitis B virus (HBV) infection, a study has shown. Importantly, smoking exerts a significant effect on the said association.
Jairia Dela Cruz, 09 Aug 2017
Multiple consecutive endoscopies with persistent non-neoplastic Barrett’s oesophagus do not appear to be a protective factor against the risk of oesophageal adenocarcinoma (EAC), according to a team of US-based investigators.
04 Aug 2017
Regardless of practice setting, the rates of adherence to hepatitis B virus (HBV) guidelines are unsatisfactory and influenced by several provider, patient and practice factors, reports a study.
03 Aug 2017
Faecal microbiota transplant (FMT) is more effective than placebo for induction of remission in patients with ulcerative colitis (UC), while having no major short-term safety signals, according to a meta-analysis.
03 Aug 2017
Corticosteroids combined with the antibiotic moxifloxacin may be effective for the management of acute acalculous cholecystitis (AAC) with systemic lupus erythematosus (SLE), suggests a new observational study.
Jairia Dela Cruz, 02 Aug 2017
Strenuous exercise appears to exert a negative, albeit reversible, impact on gastrointestinal integrity and function, according to a team of Australia-based researchers. The extent of the said gastrointestinal changes may increase further depending on the intensity and duration of exercise.
Special Reports
12 Jul 2017
DUKORAL – Inactivated Vibrio cholerae O1 serogroup & recombinant cholera toxin B subunit (WC/rCTB) vaccine (oral) – AJ Biologics
20 Mar 2017
At the recent Asian Pacific Digestive Week (APDW) 2016 held in Kobe, Japan, three prominent international experts shared their views on gastroesophageal reflux disease (GERD) and the challenges of its management.
04 Jan 2017
Recently, randomized controlled trials and guidelines have brought to light the benefits of extending the duration of H. pylori treatment. Below are summaries of guidelines and trials examining the regimens used to manage the infection.
14 Dec 2016
At the recent Annual Scientific Congress of the Malaysian Society of Gastroenterology and Hepatology (GUT 2016), held at Shangri-La Hotel, Kuala Lumpur, an expert from Hong Kong spoke on the role of direct-acting antivirals as well as pan-genotypic agents that are set to revolutionize hepatitis C treatment.
Jairia Dela Cruz, 06 Dec 2016
Sorafenib appears to be well-tolerated in patients with hepatocellular carcinoma (HCC), with the subgroup of Child-Pugh B patients having a shorter treatment duration and higher serious adverse event (SAE) incidence, according to the results of a subgroup analysis of GIDEON*.
01 Dec 2016
An expert panel meeting on hepatorenal syndrome (HRS) was recently convened in Kuala Lumpur with the aim of discussing management practices in different hospital settings. Chaired by Professor Sanjiv Mahadeva, consultant gastroenterologist, University Malaya Medical Centre, the meeting saw local and regional experts share HRS cases they have encountered in their practice.
21 Jul 2016
As its name suggests, inflammatory bowel disease (IBD), which encompasses ulcerative colitis and Crohn’s disease, involves chronic inflammation of the digestive tract. IBD is a common disease in the West, afflicting more than 5 million people.2 Although IBD is still rare in Southeast Asia, the incidence appears to be on the rise in Malaysia, with a rate of 0.67 per 100,000 population.3 It is noteworthy that early detection and management of IBD can reduce a significant amount of pain and stress for patients. Thus, general practitioners (GPs), who are experts trained to work in the front line of a healthcare system, play a vital role in reducing the burden of IBD through immediate referral of suspected IBD patients for specialist investigations.
Conference Reports
Pearl Toh, 09 Mar 2017
Pearl Toh finds out from Professor Anna Lok, director of clinical hepatology at the University of Michigan in Ann Arbor, Michigan, US, on integrating guidelines, research data, and clinical setting in decision making for management of hepatitis B during the recent Asian Pacific Association for the Study of the Liver Annual Meeting held in Shanghai, China.

Pearl Toh, 08 Mar 2017
Add-on of pegylated interferon (pegIFN) to nucleos(t)ide analogues (NA) therapy may be a better strategy than a switch from NA to pegIFN in patients with chronic hepatitis B (CHB) who are on long-term NA therapy, according to data from an interim analysis of the SWAP* study presented at the recent Asian Pacific Association for the Study of the Liver Annual Meeting (APASL 2017) held in Shanghai, China.
Pearl Toh, 24 Feb 2017
The goal of treatment for portal hypertension varies depending on the different stages and substages of cirrhosis, and hence, pharmacological therapies for managing portal hypertension should be considered in the context of other complications of cirrhosis, according to a presentation at the recent APASL 2017 held in Shanghai, China recently.
24 Feb 2017
Slideshow: Highlights from the 26th Conference of the Asian Pacific Association for the Study of the Liver (APASL), Shanghai, China, February 15 - 19.
Roshini Claire Anthony, 23 Feb 2017

The use of statins is associated with a lower risk of pyogenic liver abscess, according to a Taiwan population-based case-control study. 

Roshini Claire Anthony, 22 Feb 2017

Individuals with hepatitis C virus (HCV) infection who achieve a sustained virological response (SVR) have improved liver stiffness and a lower risk of hepatocellular carcinoma (HCC), according to a presentation at the Asian Pacific Association for the Study of the Liver annual meeting (APASL 2017) in Shanghai, China.

Jairia Dela Cruz, 22 Feb 2017
An 8- to 16-week treatment regimen of elbasvir/grazoprevir plus sofosbuvir with or without ribavirin appears to be highly effective and well tolerated in both treatment-naïve and treatment-experienced cirrhotic patients with hepatitis C virus (HCV) genotype 3 (GT3) infection, according to the results of the C-ISLE study presented at the 26th Conference of the Asian Pacific Association for the Study of the Liver (APASL) held in Shanghai, China.